Eikon Therapeutics director granted 25,873 stock options

Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/04/2026 - 05:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.

Eikon Therapeutics, Inc. reported that director Robert Luther Huffines received a grant of stock options covering 25,873 shares of the company’s stock. These options were awarded as a form of compensation and will vest in equal monthly installments over 48 months, as long as he continues in service during that period.

Insider Trade Summary

Grant/Award: 25,873 shares

Grant/Award 1 txn

Insider Huffines Robert Luther

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,873	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,873 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 25,873 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Eikon Therapeutics (EIKN) report?

Eikon Therapeutics reported a director receiving a stock option grant for 25,873 shares. The award reflects equity-based compensation and is structured to vest gradually over time, aligning the director’s interests with long-term company performance and continued service.

Who at Eikon Therapeutics (EIKN) received the stock option grant?

Director Robert Luther Huffines received the stock option grant. He serves on the company’s board and the award represents equity compensation, giving him the right to acquire up to 25,873 shares if vesting and other conditions are satisfied over the designated period.

How many shares are covered by the EIKN director’s stock option?

The stock option grant covers 25,873 shares of Eikon Therapeutics common stock. This entire amount is subject to a long-term vesting schedule, meaning the director earns the right to exercise portions of the option gradually rather than all at once.

What is the vesting schedule for the Eikon Therapeutics stock options?

One forty-eighth of the option shares vest each month over 48 months. Vesting occurs on each monthly anniversary of the vesting start date and is conditioned on the director’s continued service through each vesting date, encouraging ongoing board involvement.

Is the Eikon Therapeutics Form 4 transaction a purchase or a grant?

The Form 4 shows a grant or award acquisition of stock options, not an open-market purchase. The director did not buy existing shares; instead, he received rights to acquire 25,873 shares over time, subject to vesting conditions and continued service requirements.

Does the director immediately own all 25,873 EIKN shares from this option grant?

No, the director does not immediately own all 25,873 shares. He gains the right to exercise the option as it vests monthly over 48 months. Only vested portions become exercisable, and unvested portions remain contingent on continued qualifying service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huffines Robert Luther

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		25,873		(1)	03/01/2036	Common Stock	25,873	$0	25,873	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.